Phaseline

Targets › SLC5A1

SLC5A1 (Sodium/glucose cotransporter 1): drug programs, companies and trials

3 programs from 3 companies in 8 trials: 4 Phase 3, 3 Phase 2, 1 Phase 1; Metabolic and endocrine, Cardiovascular, Gastroenterology; next expected readout Jan 2027.

Electrogenic Na(+)-coupled sugar symporter that actively transports D-glucose or D-galactose at the plasma membrane, with a Na(+) to sugar coupling ratio of 2:1. Transporter activity is driven by a transmembrane Na(+) electrochemical gradient set by the Na(+)/K(+) pump. (UniProt, P13866)

Open in Phaseline: the race on SLC5A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Colgate Palmolive0.45% SnF HW with NaF (1450 F)
Stannous fluoride with sodium fluoride for topical fluoride delivery and antimicrobial act
SLC5A1Phase 3PlaqueJan 2027
Lexicon PharmaceuticalsSotagliflozin
Sodium/glucose cotransporter 1 inhibitor; Sodium/glucose cotransporter 2 inhibitor
SLC5A1, SLC5A2Phase 3Obstructive Cardiomyopathy, Hypertrophic; Diabetic Nephropathies; Cardiovascular Diseases; Type 1 DiabetesJan 2027
VogenxMizagliflozin 5 mg
SGLT1 inhibitor
SLC5A1Phase 2Postbariatric HypoglycemiaOct 2027

Conditions

Type 1 Diabetes (2) Postbariatric Hypoglycemia (2) Obstructive Cardiomyopathy, Hypertrophic (1) Diabetic Nephropathies (1) Cardiovascular Diseases (1) Plaque (1)

Modalities

small molecule (3)

Companies

Lexicon Pharmaceuticals (1) Colgate Palmolive (1) Vogenx (1)

Related targets

SLC5A2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.